Anthera Pharmaceuticals, Inc. (ANTH)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Anthera Pharmaceuticals, Inc. (ANTH) with AI Score 41/100 (Weak). Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for unmet medical needs. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Anthera Pharmaceuticals, Inc. (ANTH) Healthcare & Pipeline Overview
Anthera Pharmaceuticals, Inc. operates in the biotechnology sector, focusing on developing therapies for unmet medical needs. Their pipeline features Sollpura, a non-porcine pancreatic enzyme replacement therapy, and Blisibimod, targeting autoimmune diseases. The company navigates the competitive landscape of biopharmaceutical development with licensing agreements to bolster its portfolio.
Investment Thesis
Anthera Pharmaceuticals, Inc. presents a high-risk, high-reward investment profile within the biotechnology sector. The company's value hinges on the successful completion of clinical trials for Sollpura and Blisibimod. Positive Phase III results for Sollpura could drive significant market capitalization growth, addressing the unmet need for non-porcine pancreatic enzyme replacement therapy. However, the company's OTC listing and negative beta of -123.12 indicate substantial volatility and speculative trading. The lack of current revenue and reliance on future drug approvals create significant financial risk. Investors should closely monitor clinical trial outcomes and regulatory milestones to assess the potential for long-term value creation. The company's success is contingent on navigating the complex regulatory landscape and securing commercial partnerships.
Based on FMP financials and quantitative analysis
Key Highlights
- Sollpura is in Phase III clinical trial for exocrine pancreatic insufficiency, representing a potential near-term value driver.
- Blisibimod is in Phase II clinical trial for B-cell mediated autoimmune diseases, indicating a longer-term growth opportunity.
- The company has license agreements with Amgen, Inc., and Eli Lilly and Company, providing potential revenue streams and validation of its technology.
- Anthera Pharmaceuticals, Inc. operates with a small team of 21 employees, suggesting a lean operational structure.
- The company's stock trades on the OTC market, indicating higher risk and volatility compared to major exchange listings.
Competitors & Peers
Strengths
- Innovative pipeline of drug candidates targeting unmet medical needs.
- Strategic partnerships with major pharmaceutical companies.
- Potential for orphan drug designation for certain therapies.
- Lean operational structure with a small team of employees.
Weaknesses
- Limited financial resources and reliance on external funding.
- High risk of clinical trial failures and regulatory setbacks.
- Lack of established revenue streams and commercial infrastructure.
- OTC market listing indicating higher risk and volatility.
Catalysts
- Upcoming: Results from Phase III clinical trial of Sollpura for exocrine pancreatic insufficiency.
- Upcoming: Data readout from Phase II clinical trial of Blisibimod for B-cell mediated autoimmune diseases.
- Ongoing: Potential for new licensing agreements with pharmaceutical companies.
- Ongoing: Regulatory milestones and potential FDA approval for Sollpura.
- Ongoing: Progress in expanding the company's pipeline through research and development.
Risks
- Potential: Failure of clinical trials for Sollpura or Blisibimod.
- Potential: Regulatory setbacks and delays in drug approval process.
- Ongoing: Competition from established pharmaceutical companies and emerging biotechs.
- Ongoing: Limited financial resources and reliance on external funding.
- Ongoing: OTC market listing indicating higher risk and volatility.
Growth Opportunities
- Expansion into New Therapeutic Areas: Anthera could leverage its expertise in drug development to expand into new therapeutic areas with unmet medical needs, such as rare diseases or oncology. This diversification could reduce the company's reliance on its current pipeline and create new revenue streams. The market for rare disease therapies is projected to reach $258 billion by 2030, offering significant growth potential.
- Geographic Expansion: Anthera could expand its commercial operations into new geographic markets, particularly in Asia and Europe, where there is a growing demand for advanced therapies. This expansion could increase the company's revenue and market share. The global pharmaceutical market is expected to reach $1.5 trillion by 2026, with emerging markets driving much of the growth.
- Strategic Partnerships and Acquisitions: Anthera could pursue strategic partnerships or acquisitions to expand its pipeline, access new technologies, or strengthen its market position. This could accelerate the company's growth and create synergies. The biotechnology industry is characterized by frequent mergers and acquisitions, with companies seeking to consolidate their market share and expand their capabilities.
- Orphan Drug Designation: Anthera can pursue orphan drug designation for its therapies targeting rare diseases. This designation provides incentives such as market exclusivity, tax credits, and reduced regulatory fees, enhancing the commercial viability of these products. The orphan drug market is growing rapidly, driven by increasing awareness of rare diseases and the development of new therapies.
- Advancements in Drug Delivery Technologies: Anthera can invest in innovative drug delivery technologies to improve the efficacy and patient compliance of its therapies. This could create a competitive advantage and increase the market potential of its products. The drug delivery market is expected to reach $240 billion by 2028, driven by the development of new and improved delivery systems.
Opportunities
- Expansion into new therapeutic areas and geographic markets.
- Strategic acquisitions or licensing agreements to expand the pipeline.
- Advancements in drug delivery technologies to improve efficacy.
- Growing demand for therapies targeting rare diseases and autoimmune disorders.
Threats
- Competition from established pharmaceutical companies and emerging biotechs.
- Changes in regulatory policies and reimbursement models.
- Product liability claims and intellectual property disputes.
- Economic downturns and market volatility affecting funding availability.
Competitive Advantages
- Patented drug formulations and delivery systems.
- Clinical trial data demonstrating efficacy and safety.
- Regulatory exclusivity for approved therapies.
- Established partnerships with major pharmaceutical companies.
About ANTH
Founded in 2004 and based in Houston, Texas, Anthera Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative medicines for patients with unmet medical needs. The company's primary focus is on addressing diseases with limited or inadequate treatment options, striving to improve patient outcomes and quality of life. Anthera's lead product candidates include Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy currently in Phase III clinical trials for the treatment of exocrine pancreatic insufficiency (EPI). EPI is a condition where the pancreas does not produce enough enzymes to digest food properly. Additionally, Anthera is developing Blisibimod, a drug in Phase II clinical trials for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy (IgA nephropathy), a kidney disease. Anthera has established strategic collaborations through license agreements with major pharmaceutical companies like Amgen, Inc., and Eli Lilly and Company, enhancing its research and development capabilities and expanding its therapeutic pipeline. The company's commitment to innovation and patient-centric drug development positions it within the competitive biotechnology landscape.
What They Do
- Develops Sollpura, a non-porcine pancreatic enzyme replacement therapy.
- Conducts Phase III clinical trials for Sollpura to treat exocrine pancreatic insufficiency.
- Develops Blisibimod for B-cell mediated autoimmune diseases.
- Conducts Phase II clinical trials for Blisibimod to treat IgA nephropathy.
- Establishes license agreements with pharmaceutical companies like Amgen and Eli Lilly.
- Focuses on addressing unmet medical needs through innovative drug development.
- Aims to improve patient outcomes and quality of life through targeted therapies.
Business Model
- Develops and patents novel pharmaceutical products.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Out-licenses or commercializes approved therapies.
Industry Context
Anthera Pharmaceuticals, Inc. operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The industry is driven by innovation, with companies constantly seeking to develop novel treatments for unmet medical needs. Anthera's focus on exocrine pancreatic insufficiency and autoimmune diseases positions it within specific niches of the broader pharmaceutical market. Competitors include companies developing similar therapies, as well as established pharmaceutical giants. The company's success depends on its ability to navigate the regulatory landscape, secure funding, and effectively commercialize its products.
Key Customers
- Patients with exocrine pancreatic insufficiency (EPI).
- Patients with B-cell mediated autoimmune diseases, including IgA nephropathy.
- Healthcare providers who prescribe and administer Anthera's therapies.
- Pharmaceutical companies that partner with Anthera through licensing agreements.
Financials
Chart & Info
Anthera Pharmaceuticals, Inc. (ANTH) stock price: Price data unavailable
Latest News
-
Anthera Pharmaceuticals (OTCMKTS:ANTH) Stock Passes Above Two Hundred Day Moving Average – What’s Next?
defenseworld.net · Feb 21, 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ANTH.
Price Targets
Wall Street price target analysis for ANTH.
MoonshotScore
What does this score mean?
The MoonshotScore rates ANTH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul F. Truex
CEO
Paul F. Truex serves as the Chief Executive Officer of Anthera Pharmaceuticals, Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on corporate strategy, business development, and commercialization. He has held leadership positions at various companies, contributing to the development and launch of several successful pharmaceutical products. His expertise spans across multiple therapeutic areas, including gastroenterology and immunology. Truex's experience also includes roles in finance and operations, providing a well-rounded perspective on the biopharmaceutical business.
Track Record: Under Paul F. Truex's leadership, Anthera Pharmaceuticals has focused on advancing its clinical pipeline, particularly Sollpura and Blisibimod. He has overseen the progression of these drug candidates through clinical trials and has secured strategic partnerships to support their development. Key milestones include the initiation and ongoing execution of Phase III trials for Sollpura and Phase II trials for Blisibimod. His tenure has been marked by efforts to navigate the challenging regulatory landscape and secure funding for the company's research and development programs.
ANTH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Anthera Pharmaceuticals, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information, price volatility, and illiquidity. This tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for price manipulation and pump-and-dump schemes.
- Higher risk of fraud and mismanagement.
- Limited liquidity and wider bid-ask spreads.
- Lack of regulatory oversight and investor protection.
- Verify the company's legal status and registration.
- Review the company's financial statements, if available.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Consult with a financial advisor and conduct thorough research.
- Understand the risks associated with investing in OTC stocks.
- Established partnerships with reputable pharmaceutical companies (Amgen, Eli Lilly).
- Advancement of drug candidates through clinical trials (Phase III for Sollpura, Phase II for Blisibimod).
- Focus on addressing unmet medical needs in specific therapeutic areas.
- Experienced management team with a background in the pharmaceutical industry.
What Investors Ask About Anthera Pharmaceuticals, Inc. (ANTH)
What does Anthera Pharmaceuticals, Inc. do?
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for patients with unmet medical needs. Their primary focus is on developing therapies for exocrine pancreatic insufficiency (EPI) and B-cell mediated autoimmune diseases. Their lead product candidates include Sollpura, a non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for EPI, and Blisibimod, a drug in Phase II clinical trials for autoimmune diseases. The company aims to improve patient outcomes by addressing conditions with limited treatment options.
What do analysts say about ANTH stock?
As of March 15, 2026, formal analyst ratings for Anthera Pharmaceuticals, Inc. (ANTH) are unavailable, likely due to its OTC listing and limited market capitalization. Given the company's focus on clinical-stage drug development, valuation is highly dependent on the success of Sollpura and Blisibimod clinical trials. Investors should closely monitor trial results and regulatory milestones, as these will be key drivers of future valuation. The company's financial position and cash runway are also critical factors to consider, given the high costs associated with drug development.
What are the main risks for ANTH?
Anthera Pharmaceuticals, Inc. faces significant risks inherent to the biotechnology industry and its OTC market listing. Clinical trial failures for Sollpura or Blisibimod would severely impact the company's value. Regulatory hurdles and delays in obtaining FDA approval pose additional risks. Competition from larger pharmaceutical companies with greater resources is a constant threat. The company's limited financial resources and reliance on external funding make it vulnerable to market conditions. The OTC listing increases volatility and reduces liquidity, posing challenges for investors.
What are the key factors to evaluate for ANTH?
Anthera Pharmaceuticals, Inc. (ANTH) currently holds an AI score of 41/100, indicating low score. Key strength: Innovative pipeline of drug candidates targeting unmet medical needs.. Primary risk to monitor: Potential: Failure of clinical trials for Sollpura or Blisibimod.. This is not financial advice.
How frequently does ANTH data refresh on this page?
ANTH prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ANTH's recent stock price performance?
Recent price movement in Anthera Pharmaceuticals, Inc. (ANTH) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative pipeline of drug candidates targeting unmet medical needs.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ANTH overvalued or undervalued right now?
Determining whether Anthera Pharmaceuticals, Inc. (ANTH) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ANTH?
Before investing in Anthera Pharmaceuticals, Inc. (ANTH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of March 15, 2026.
- OTC market data may be limited and less reliable than major exchange data.
- Clinical trial outcomes are inherently uncertain and can significantly impact the company's value.